Novel chimeric lysin with high-Level antimicrobial activity against methicillin-Resistant staphylococcus aureus in vitro and in vivo

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 536-542

  Yang, Hang ^a   Zhang, Yun ^a   Yu, Junping ^a   Huang, Yanling ^a   Zhang, Xian En ^a   Wei, Hongping ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CHIMERIC LYSIN; LYSOSTAPHIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG EFFICACY; ENZYME ACTIVE SITE; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE;

ANIMALS; ANTI-INFECTIVE AGENTS; FEMALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUCOPROTEINS; STAPHYLOCOCCAL INFECTIONS;

EID: 84891543534     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01793-13     Document Type: Article

References (37)

1. Brumfitt W, Hamilton-Miller J. 1989. Methicillin-resistant Staphylococcus aureus. N. Engl. J. Med. 320:1188-1196. http://dx.doi.org/10.1056/ NEJM198905043201806.
2. Maple PA, Hamilton-Miller JM, Brumfitt W. 1989. World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus. Lancet i:537-540
3. Arias CA, Murray BE. 2009. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N. Engl. J. Med. 360:439-443. http://dx.doi.org/10.1056/NEJMp0804651.
4. Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer AS, Tang AW, Phung TO, Spellberg B. 2005. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med. 352:1445-1453. http://dx.doi.org/10.1056/NEJMoa042683.
5. Mylotte JM, McDermott C, Spooner JA. 1987. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Rev. Infect. Dis. 9:891-907. http://dx.doi.org/10.1093/clinids/9.5.891.
6. Enright MC. 2003. The evolution of a resistant pathogen-the case of MRSA. Curr. Opin. Pharmacol. 3:474-479. http://dx.doi.org/10.1016/S1471-4892(03) 00109-7.
7. Schuch R, Nelson D, Fischetti VA. 2002. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418:884-889. http://dx.doi.org/10. 1038/nature01026.
8. Nelson D, Loomis L, Fischetti VA. 2001. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl. Acad. Sci. U. S. A. 98:4107-4112. http://dx.doi.org/10.1073/pnas.061038398.
9. Fischetti VA. 2010. Bacteriophage endolysins: A novel anti-infective to control Gram-positive pathogens. Int. J. Med. Microbiol. 300:357-362. http://dx.doi.org/10.1016/j.ijmm.2010.04.002.
10. Rashel M, Uchiyama J, Ujihara T, Uehara Y, Kuramoto S, Sugihara S, Yagyu K, Muraoka A, Sugai M, Hiramatsu K, Honke K, Matsuzaki S. 2007. Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11. J. Infect. Dis. 196: 1237-1247. http://dx.doi.org/10.1086/521305.
11. Loeffler JM, Nelson D, Fischetti VA. 2001. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294:2170-2172. http://dx.doi.org/10.1126/science.1066869.
12. Gu J, Xu W, Lei L, Huang J, Feng X, Sun C, Du C, Zuo J, Li Y, Du T, Li L, Han W. 2011. LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection. J. Clin. Microbiol. 49:111-117. http://dx.doi.org/10.1128/JCM.01144- 10.
13. Becker SC, Foster-Frey J, Donovan DM. 2008. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA. FEMS Microbiol. Lett. 287:185-191. http://dx.doi.org/10.1111/j.1574-6968.2008.01308.x
14. O'Flaherty S, Coffey A, Meaney W, Fitzgerald GF, Ross RP. 2005. The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. J. Bacteriol. 187:7161-7164. http://dx.doi.org/10.1128/ JB.187.20.7161-7164.2005.
15. Manoharadas S, Witte A, Blasi U. 2009. Antimicrobial activity of a chimeric enzybiotic towards Staphylococcus aureus. J. Biotechnol. 139: 118-123. http://dx.doi.org/10.1016/j.jbiotec.2008.09.003
16. Fernandes S, Proenca D, Cantante C, Silva FA, Leandro C, Lourenco S, Milheirico C, de Lencastre H, Cavaco-Silva P, Pimentel M, Sao-Jose C. 2012. Novel chimerical endolysins with broad antimicrobial activity against methicillin-resistant Staphylococcus aureus. Microb. Drug Resist. 18:333-343. http://dx.doi.org/10.1089/mdr.2012.0025.
17. Idelevich EA, von Eiff C, Friedrich AW, Iannelli D, Xia G, Peters G, Peschel A, Wanninger I, Becker K. 2011. In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin. Antimicrob. Agents Chemother. 55: 4416-4419. http://dx.doi.org/10.1128/AAC.00217-11.
18. Pastagia M, Euler C, Chahales P, Fuentes-Duculan J, Krueger JG, Fischetti VA. 2011. A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and -sensitive Staphylococcus aureus strains. Antimicrob. Agents Chemother. 55:738-744. http://dx.doi.org/10.1128/ AAC.00890-10.
19. Daniel A, Euler C, Collin M, Chahales P, Gorelick KJ, Fischetti VA. 2010. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54:1603-1612. http://dx.doi.org/10.1128/AAC.01625-09.
20. Becker SC, Foster-Frey J, Stodola AJ, Anacker D, Donovan DM. 2009. Differentially conserved staphylococcal SH3b-5 cell wall binding domains confer increased staphylolytic and streptolytic activity to a streptococcal prophage endolysin domain. Gene 443:32-41. http://dx.doi.org/10.1016/j.gene.2009.04.023.
21. Grundling A, Schneewind O. 2006. Cross-linked peptidoglycan mediates lysostaphin binding to the cell wall envelope of Staphylococcus aureus. J. Bacteriol. 188:2463-2472. http://dx.doi.org/10.1128/JB.188.7.2463-2472.2006.
22. Schmelcher M, Powell AM, Becker SC, Camp MJ, Donovan DM. 2012. Chimeric phage lysins act synergistically with lysostaphin to kill mastitiscausing Staphylococcus aureus in murine mammary glands. Appl. Environ. Microbiol. 78:2297-2305. http://dx.doi.org/10.1128/AEM.07050-11.
23. Loessner MJ, Gaeng S, Scherer S. 1999. Evidence for a holin-like protein gene fully embedded out of frame in the endolysin gene of Staphylococcus aureus bacteriophage 187. J. Bacteriol. 181:4452-4460
24. Mao J, Schmelcher M, Harty WJ, Foster-Frey J, Donovan DM. 2013. Chimeric Ply187 endolysin kills Staphylococcus aureus more effectively than the parental enzyme. FEMS Microbiol. Lett. 342:30-36. http://dx.doi.org/10.1111/1574-6968. 12104.
25. Towner KJ, Talbot DC, Curran R, Webster CA, Humphreys H. 1998. Development and evaluation of a PCR-based immunoassay for the rapid detection of methicillin-resistant Staphylococcus aureus. J. Med. Microbiol. 47:607-613. http://dx.doi.org/10.1099/00222615-47-7-607.
26. Boye K, Bartels MD, Andersen IS, Moller JA, Westh H. 2007. A new multiplex PCR for easy screening of methicillin-resistant Staphylococcus aureus SCCmec types 1-5 Clin. Microbiol. Infect. 13:725-727. http://dx.doi.org/10.1111/ j.1469-0691.2007.01720.x.
27. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan H, Liassine N, Bes M, Greenland T, Reverdy ME, Etienne J. 2003. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: Worldwide emergence. Emerg. Infect.Dis. 9:978-984. http://dx.doi.org/10. 3201/eid0908.030089.
28. Yoong P, Schuch R, Nelson D, Fischetti VA. 2004. Identification of a broadly active phage lytic enzyme with lethal activity against antibioticresistant Enterococcus faecalis and Enterococcus faecium. J. Bacteriol. 186: 4808-4812. http://dx.doi.org/10.1128/JB.186.14.4808-4812.2004.
29. Yang H, Wang DB, Dong Q, Zhang Z, Cui Z, Deng J, Yu J, Zhang XE, Wei H. 2012. Existence of separate domains in lysin PlyG for recognizing Bacillus anthracis spores and vegetative cells. Antimicrob. Agents Chemother. 56:5031-5039. http://dx.doi.org/10.1128/AAC.00891-12.
30. Yoong P, Schuch R, Nelson D, Fischetti VA. 2006. PlyPH, a bacteriolytic enzyme with a broad pH range of activity and lytic action against Bacillus anthracis. J. Bacteriol. 188:2711-2714. http://dx.doi.org/10.1128/JB.188.7.2711- 2714.2006
31. Cheng Q, Nelson D, Zhu S, Fischetti VA. 2005. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob. Agents Chemother. 49:111-117. http: //dx.doi.org/10.1128/AAC.49.1.111-117.2005.
32. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
33. Gilmer DB, Schmitz JE, Euler CW, Fischetti VA. 2013. Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 57:2743-2750. http://dx.doi.org/10.1128/AAC.02526- 12.
34. Yuan W, Hu Q, Cheng H, Shang W, Liu N, Hua Z, Zhu J, Hu Z, Yuan J, Zhang X, Li S, Chen Z, Hu X, Fu J, Rao X. 2013. Cell wall thickening is associated with adaptive resistance to amikacin in methicillin-resistant Staphylococcus aureus clinical isolates. J. Antimicrob. Chemother. 68: 1089-1096. http://dx.doi.org/10.1093/jac/dks522.
35. Donovan DM, Dong S, Garrett W, Rousseau GM, Moineau S, Pritchard DG. 2006. Peptidoglycan hydrolase fusions maintain their parental specificities. Appl. Environ. Microbiol. 72:2988-2996. http://dx.doi.org/10.1128/AEM.72.4.2988- 2996.2006.
36. Schmitz JE, Ossiprandi MC, Rumah KR, Fischetti VA. 2011. Lytic enzyme discovery through multigenomic sequence analysis in Clostridium perfringens. Appl. Microbiol. Biotechnol. 89:1783-1795. http://dx.doi.org/10.1007/s00253-010- 2982-8.
37. Gu J, Lu R, Liu X, Han W, Lei L, Gao Y, Zhao H, Li Y, Diao Y. 2011. LysGH15B, the SH3b domain of staphylococcal phage endolysin LysGH15, retains high affinity to staphylococci. Curr. Microbiol. 63:538-542. http://dx.doi.org/10.1007/s00284-011-0018-y.